<DOC>
	<DOCNO>NCT00104130</DOCNO>
	<brief_summary>The purpose trial study KOS-862 men metastatic prostate cancer fail docetaxel-containing regimen .</brief_summary>
	<brief_title>Study KOS-862 ( Epothilone D ) Metastatic Prostate Cancer</brief_title>
	<detailed_description>This study Phase 2 , single arm study KOS-862 men metastatic prostate cancer fail docetaxel-containing regimen . PSA response primary end-point objective response check available .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>At least 18 year age . Metastatic disease . One previous treatment include docetaxel ( Taxotere ) . At least 3 week since last surgery/radiation/chemotherapy ECOG Performance Status 0 , 1 2 Active brain metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>prostate</keyword>
</DOC>